EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.31
-0.16 (-2.47%)
At close: 4:00PM EST

6.31 0.00 (0.00%)
After hours: 4:56PM EST

Stock chart is not supported by your current browser
Previous Close6.47
Open6.55
Bid6.24 x 1100
Ask7.15 x 4000
Day's Range6.17 - 6.55
52 Week Range6.17 - 21.40
Volume609,251
Avg. Volume651,281
Market Cap499.551M
Beta (3Y Monthly)3.26
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateMar 11, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.11
Trade prices are not sourced from all markets
  • Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?
    Zacks10 days ago

    Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire28 days ago

    Epizyme Announces Conference Call to Discuss Corporate Updates

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5172457. Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines.

  • GlobeNewswirelast month

    Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3
    Zackslast month

    Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3

    Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.

  • Epizyme (EPZM) Reports Q3 Loss, Lags Revenue Estimates
    Zackslast month

    Epizyme (EPZM) Reports Q3 Loss, Lags Revenue Estimates

    Epizyme (EPZM) delivered earnings and revenue surprises of 10.00% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Epizyme: 3Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 54 cents. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment ...

  • Business Wirelast month

    Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress

    Enrollment in Phase 2 Cohort of Follicular Lymphoma Patients with EZH2 Activating Mutations on Track to be Completed by Year End

  • Business Wire2 months ago

    Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced positive interim data from the fully enrolled epithelioid sarcoma cohort of its ongoing Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor. The data were presented by the study’s lead investigator, Mrinal Gounder, M.D., attending physician, Sarcoma Medical Oncology and Early Drug Development Services, Memorial Sloan Kettering Cancer Center, during the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. Interim data as of August 21, 2018 from the 62 patients enrolled show that tazemetostat treatment demonstrated clinically meaningful activity for patients with epithelioid sarcoma (ES).

  • Simply Wall St.2 months ago

    What Kind Of Investor Owns Most Of Epizyme Inc (NASDAQ:EPZM)?

    Every investor in Epizyme Inc (NASDAQ:EPZM) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders Read More...

  • Barrons.com2 months ago

    Big Biotech Investors Poured $29 Million Into 2 Battered Companies

    RA Capital and Longitude Capital bought more shares of a firm developing a treatment for eye diseases. NEA invested more in a firm working on cancer treatments.

  • Business Wire2 months ago

    Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study Cohort in Epithelioid Sarcoma at ESMO

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany. Tazemetostat is the company’s potent, selective, orally available, first-in-class EZH2 inhibitor. The Phase 2 study ES cohort completed enrollment in 2017 with a total of 62 patients.

  • Business Wire2 months ago

    Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $9.00 per share, which includes 1,250,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price less the underwriting discount. The aggregate gross proceeds to Epizyme from the offering, before deducting underwriting discounts and offering expenses, are $86.25 million.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Boston Scientific Corporation (NYSE: BSX ) Eli Lilly ...

  • CNBC2 months ago

    After-hours buzz: TPX, JCP & more

    Check out the companies making headlines after the bell: Tempur Sealy International TPX shares jumped more than 8 percent in after-hours trading following reports that competitor Mattress Firm is preparing to file for bankruptcy.

  • Business Wire2 months ago

    Epizyme Announces Proposed Public Offering of Common Stock

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Epizyme.

  • FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study
    Zacks3 months ago

    FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study

    The FDA lifts partial clinical hold on Epizyme's lead pipeline candidate, tazemetostat's study.

  • MarketWatch3 months ago

    Epizyme's stock soars after FDA lifts hold on trial enrollments

    Shares of Epizyme Inc. shot up 25% in premarket trade Monday, after the company said the Food and Drug Administration lifted its hold on the enrolling of new patients in trials of its treatment for non-Hodgkin lymphoma. The FDA's hold had followed a report of a case of T-cell lymphoblastic lymphoma (T-LBL) in its tazemetostat pediatric study. Epizyme said its response to the FDA included a comprehensive assessment of the risk of secondary malignancies. "The Epizyme team has worked diligently to provide a comprehensive response back to the FDA, and through constructive dialogue, we successfully resolved the partial clinical hold," said Chief Executive Robert Bazemore. "This allows us to turn our full attention to our key priorities: preparing for our first NDA submission for tazemetostat in epithelioid sarcoma and defining our registration path in FL." The stock had tumbled 31% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF had gained 5.6% and the S&P 500 had advanced 6.3%.

  • Business Wire3 months ago

    Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. Epizyme is now in the process of reopening enrollment in all of its company-sponsored trials in the U.S., including the follicular lymphoma (FL) EZH2 activating mutation cohort of its Phase 2 non-Hodgkin lymphoma trial. Epizyme’s formal response to the FDA included a comprehensive assessment of the risk of secondary malignancies, including T-cell lymphoblastic lymphoma (T-LBL) potentially associated with tazemetostat, which took into account both published literature and the company’s clinical experience to date.

  • Business Wire3 months ago

    Epizyme to Participate in Upcoming Investor Conferences

    Epizyme, Inc. , a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor confer

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of EPZM earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Epizyme Inc Earnings Call

  • Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks
    Zacks4 months ago

    Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks

    Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.

  • Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks4 months ago

    Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

    Epizyme (EPZM) delivered earnings and revenue surprises of 20.75% and 458.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss
    Zacks4 months ago

    Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss

    Epizyme (EPZM) reports narrower-than-expected loss and revenues beat estimates in the second quarter of 2018.